Skip to main content

Table 1 Summary of clinical HIV remission trials in the RV254/SEARCH010 cohort in Bangkok, Thailand

From: Leveraging early HIV diagnosis and treatment in Thailand to conduct HIV cure research

Study Inclusion criteria Number of participants Dose and duration of investigational agent Duration of ATI Key findings Ref.
RV 411 Fiebig I, on ART for ≥ 96 weeks, HIV RNA < 50 copies/mL for ≥ 48 weeks, integrated HIV DNA in PBMCs of < 10 copies/106 PBMCs, and CD4 T cell of ≥ 400 cells/mm3 8 N/A (study of early ART only) Up to 24 weeks Viral rebound was observed in all participants and at a median time of 26 days. ART started in Fiebig I stage did not prevent or delay viral rebound [59]
RV 397 Fiebig I–III, on ART for ≥ 96 weeks, HIV RNA < 50 copies/mL for ≥ 48 weeks, integrated HIV DNA in PBMCs of < 10 copies/106 PBMCs, and CD4 T cell of ≥ 400 cells/mm3 18 VRC01 40 mg/kg IV every 3 weeks for up to 24 weeks Up to 48 weeks VRC01 was generally safe and was associated with a trend toward delayed viral rebound: the placebo group experienced viral rebound at a median of 14 days, whereas participants in the VRC01 group at a median of 26 days [60]
RV 409 Fiebig III–IV, on ART for ≥ 42 weeks, HIV RNA < 50 copies/mL for ≥ 28 weeks, CD4 T cell of ≥ 450 cells/mm3 15 Vorinostat PO 400 mg/day 14 days on/off (3 cycles), hydroxychloroquine PO 200 mg BID, maraviroc PO 600 mg BID for 10 weeks Up to 24 weeks VHM was well tolerated in the majority of participants. No changes in total HIV DNA in PBMCs were described. All Fiebig III/IV treated participants had viral rebound after ATI; median time to viral rebound was 22 days [61]
RV 405 Fiebig I–IV, on ART for ≥ 4 weeks, HIV RNA < 50 copies/mL for ≥ 48 weeks, CD4 T cell of ≥ 400 cells/mm3 26 Ad26 vaccine 5 * 1010 viral particle per 0.5 mL IM at week 0 and 12, MVA vaccine 108 plaque-forming unit per 0.5 mL IM at week 24 and 48 Up to 36 weeks Ad26/MVA was well-tolerated and it contributed to a modest delay in time to viral rebound after analytic treatment interruption [62]
  1. pts. participants, ref. reference, ART antiretroviral therapy, PBMCs peripheral blood mononuclear cells, IV intravenous, PO per os, Ad26 adenovirus type 26 vector prime, IM intramuscular, MVA modified vaccinia Ankara